Cowen & Co. analyst Ken Cacciatore maintained a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report) on April 25 and set a price target of $30.00. The company's shares closed last Thursday at $10.85, close to its 52-week low of $9.70. According to TipRanks.com, Cacciatore is a 1-star analyst with an average return of -1.2% and a 40.2% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Molecular Partners AG, Jazz Pharmaceuticals, and Aerie Pharma. Aurinia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $24.44, implying an 116.5% upside from current levels.
https://www.tipranks.com/news/blurbs/cowen-co-thinks-aurinia-pharmaceuticals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Aurinia Pharmaceuticals Charts.
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Aurinia Pharmaceuticals Charts.